Eli Lilly and Company
NYSE:LLY · New York Stock Exchange
-$10.54 today
Vol 2.77M · Avg 3.19M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
77.8%
avg 74.4%
ROIC
30.2%
avg 17.6%
ROA
18.3%
avg 10.8%
Analysis
ROE is currently the strongest return metric at 77.8% versus its period average of 74.4%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
David A. Ricks | Chairman & CEO | $8.92M | — | 58 | $571,715.10 | 0.06% |
Daniel Skovronsky | Chief Scientific & Product Officer and President of Lilly Research Laboratories | $4.90M | — | 52 | $160,071.73 | 0.02% |
Anat Hakim | Executive Vice President, General Counsel & Secretary | $3.34M | — | 57 | $22,987.02 | <0.01% |
Lucas E. Montarce | Executive Vice President & Chief Financial Officer | $3.24M | — | 48 | $0.00 | <0.01% |
Jacob S. Van Naarden | Executive VP, President of Lilly Oncology & Head of Corporate Business Development | $3.00M | — | 41 | $26,626.50 | <0.01% |
Patrik Jonsson | Executive VP & President of Lilly International | $1.67M | — | 59 | $60,646.62 | <0.01% |
Diogo Rau | Executive VP and Chief Information & Digital Officer | $1.06M | — | 51 | $26,229.69 | <0.01% |
Donald A. Zakrowski | Senior Vice President of Finance & Chief Accounting Officer | — | — | — | $3,607.44 | <0.01% |
Eric Dozier | Executive Vice President & Chief People Officer | — | — | 59 | $14,455.21 | <0.01% |
Frank Cunningham | Senior Vice President of Global Value & Access | — | — | — | — | — |
Ilya Yuffa | Executive VP and President of Lilly USA & Global Customer Capabilities | — | — | 51 | $29,804.11 | <0.01% |
Michael Czapar | Director of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
110
$1.05B
Net Sentiment
$1.05B
Net selling
Most Active
LILLY ENDOWMENT INC
109 transactions
1–10 of 110
Analysis
Insiders reported 0 buys worth $0.00 and 110 sells worth $1.05B over the last 12 months. That adds up to net selling of $1.05B. LILLY ENDOWMENT INC was the most active insider with 109 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -15.2% | +25.2% (15yr)6 analysts |
| Revenue | N/A | N/A | -4.1% | +13.3% (15yr)11 analysts |
| Net Income | N/A | N/A | -16.2% | +23.5% (15yr)11 analysts |
| EBIT | N/A | N/A | -10.5% | +16.7% (15yr)11 analysts |
Analysis
Recent growth has been strongest in Revenue at -4.1% over three years. Forward estimates point to EPS at +25.2% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Johnson & Johnson
NYSE:JNJ
$552.89B
AbbVie Inc.
NYSE:ABBV
$382.93B
Merck & Co., Inc.
NYSE:MRK
$282.33B
Novartis AG
NYSE:NVS
$281.96B
AstraZeneca PLC
NYSE:AZN
$271.39B
Novo Nordisk A/S
NYSE:NVO
$191.48B
Amgen Inc.
NASDAQ:AMGN
$180.94B
Gilead Sciences, Inc.
NASDAQ:GILD
$152.75B
Pfizer Inc.
NYSE:PFE
$144.02B
Sanofi
NASDAQ:SNY
$101.57B
Who manages LLY?
Eli Lilly and Company (LLY) lists 12 active executives. The top listed executive is Anat Hakim, Executive Vice President, General Counsel & Secretary.
Are LLY insiders buying or selling?
Recent insider activity shows net selling of $980.21M.
Explore More
Continue the stock analysis
Jump to another research area for this company.